FDA breakthrough status for Bluejay’s CHD therapy brelovitug
The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta (CHD).
The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta (CHD).
What's Your Reaction?
